H.C. Wainwright analyst Robert Burns has reiterated their bullish stance on HURA stock, giving a Buy rating on August 18.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Robert Burns has given his Buy rating due to a combination of factors including TuHURA Biosciences’ strategic financial projections and upcoming catalysts. Despite reporting a wider-than-expected net loss for 2Q25, the company maintains a strong cash position and plans for an additional equity raise, which supports its financial stability and growth potential.
Looking forward, significant upcoming catalysts such as the Phase 3 trial update for IFx-2.0 and the initiation of a Phase 2 trial for a VISTA-targeted mAb in AML are expected to drive future value. The valuation, based on a discounted cash flow analysis, reflects a favorable market outlook with a 12-month price target of $12 per share. However, investors should be aware of risks including potential negative clinical results and regulatory challenges.
In another report released on August 18, Maxim Group also maintained a Buy rating on the stock with a $15.00 price target.